These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8856294)

  • 1. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient.
    Panuccio V; Enia G; Parlongo S; Cutrupi S; Zoccali C
    Nephron; 1996; 73(4):736. PubMed ID: 8856294
    [No Abstract]   [Full Text] [Related]  

  • 2. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
    Weissgarten J; Zaidenstein R; Fishman S; Dishi V; Michovitz-Koren M; Averbukh Z; Golik A
    Perit Dial Int; 1999; 19(2):180-2. PubMed ID: 10357195
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute rhabdomyolysis after bezafibrate re-exposure.
    Terrovitou CT; Milionis HJ; Elisaf MS
    Nephron; 1998; 78(3):336-7. PubMed ID: 9546698
    [No Abstract]   [Full Text] [Related]  

  • 4. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment.
    Górriz JL; Sancho A; Alcoy E; García-Ramos JL; Pallardó LM
    Nephrol Dial Transplant; 1995 Dec; 10(12):2371-2. PubMed ID: 8808248
    [No Abstract]   [Full Text] [Related]  

  • 5. Mizoribine-induced rhabdomyolysis in a rheumatoid arthritis patient receiving bezafibrate treatment.
    Morimoto S; Fujioka Y; Tsutsumi C; Masai M; Okumura T; Yuba M; Sakoda T; Tsujino T; Ohyanagi M
    Am J Med Sci; 2005 Apr; 329(4):211-3. PubMed ID: 15832106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine--a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate.
    Plotkin E; Bernheim J; Ben-Chetrit S; Mor A; Korzets Z
    Nephrol Dial Transplant; 2000 May; 15(5):740-1. PubMed ID: 10809833
    [No Abstract]   [Full Text] [Related]  

  • 7. Bone scintigraphy of drug-induced rhabdomyolysis: antihyperlipidemia agent.
    Takayama T; Tsuji S; Taki J; Michigishi T; Tonami N
    Clin Nucl Med; 1996 Dec; 21(12):988-9. PubMed ID: 8957627
    [No Abstract]   [Full Text] [Related]  

  • 8. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism.
    Clouâtre Y; Leblanc M; Ouimet D; Pichette V
    Nephrol Dial Transplant; 1999 Apr; 14(4):1047-8. PubMed ID: 10328516
    [No Abstract]   [Full Text] [Related]  

  • 9. Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.
    Chan MK
    Nephron; 1990; 56(1):56-61. PubMed ID: 2234250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bezafibrate-induced myoglobinuric kidney failure in a 54-year-old patient with diabetes mellitus type IIa].
    Cissewski K; Kienast K; Windeck R; Benker G; Reinwein D
    Med Klin (Munich); 1988 Mar; 83(5):174-7. PubMed ID: 3374444
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.
    Yang KC; Fang CC; Su TC; Lee YT
    Am J Kidney Dis; 2005 Mar; 45(3):e57-60. PubMed ID: 15754265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated blood concentrations of cyclosporine and kidney failure after bezafibrate in renal graft recipient.
    Hirai M; Tatuso E; Sakurai M; Ichikawa M; Matsuya F; Saito Y
    Ann Pharmacother; 1996; 30(7-8):883-4. PubMed ID: 8826580
    [No Abstract]   [Full Text] [Related]  

  • 13. Endstage renal failure due to polycystic kidney disease managed by continuous ambulatory peritoneal dialysis.
    Graham AN; Neale TJ; Hatfield PJ; Morrison RB; Meech PR; Jacobson A; Faircloth C
    N Z Med J; 1986 Jul; 99(805):491-3. PubMed ID: 3461382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function changes in diabetic nephropathy induced by bezafibrate.
    Bruce R; Daniels A; Cundy T
    Nephron; 1996; 73(3):490. PubMed ID: 8832617
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bezafibrate-induced rhabdomyolysis in a patient with impaired kidney function].
    Haubenstock A; Schmidt P; Zazgornik J; Balcke P; Kopsa H; Sertl K
    Dtsch Med Wochenschr; 1984 Jan; 109(4):157-8. PubMed ID: 6692783
    [No Abstract]   [Full Text] [Related]  

  • 16. [Continuous ambulatory peritoneal dialysis in bilateral polycystic kidney disease].
    Cancarini GC
    Minerva Urol Nefrol; 1987; 39(3):287-90. PubMed ID: 3438799
    [No Abstract]   [Full Text] [Related]  

  • 17. Bezafibrate-induced rhabdomyolysis.
    Malnick SD; Badir A; Landau Z
    DICP; 1991; 25(7-8):869-70. PubMed ID: 1949949
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rhabdomyolysis due to bezafibrate: a new case].
    Gas JM; Prados MC; Perdiguero M; Rivera F
    Med Clin (Barc); 1992 Feb; 98(4):156-7. PubMed ID: 1552772
    [No Abstract]   [Full Text] [Related]  

  • 19. Polycystic kidney disease and late peritoneal leakage in CAPD: are they related?
    De V; Scalamogna A; Scanziani R; Castelnovo C; Dozio B; Rovere G
    Perit Dial Int; 2002; 22(1):82-4. PubMed ID: 11929149
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rhabdomyolysis caused by antilipemic agents in a patient with terminal nephropathy undergoing continuous ambulatory peritoneal dialysis (CAPD)].
    Santa Cruz PL; Barile M; Sánchez O; Agüero F
    Nefrologia; 2002; 22(1):87-8. PubMed ID: 11987693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.